Abstract
Neuroblastoma (NB) is a highly heterogeneous extracranial solid tumor in children. While its clinical presentation varies, periorbital metastasis—often manifesting as "raccoon eyes"—is a hallmark of advanced, high-risk disease. This study retrospectively analyzed 40 patients to summarize the clinical characteristics and short-term prognosis of this specific subgroup. The findings reveal that periorbital involvement is associated with universal systemic spread, high rates of MYCN amplification, and a dismal 5-year overall survival rate of 16%.
Introduction
Neuroblastoma is the most common extracranial solid tumor in the pediatric population. Its clinical course can range from spontaneous regression to rapid, fatal progression. Patients presenting with periorbital metastasis represent a particularly aggressive subset. These symptoms often lead parents to seek initial consultation with ophthalmologists, potentially delaying the diagnosis of the underlying systemic malignancy. This paper details the clinical profile, genetic markers, and outcomes for these high-risk patients to improve diagnostic awareness and prognostic accuracy.
Methods
The study cohort consisted of 40 pediatric patients (25 boys, 15 girls) treated at the Hematology-Oncology Center of Beijing Children’s Hospital between March 2007 and March 2018.
Staging and Treatment
All patients were staged according to the International Neuroblastoma Staging System (INSS) and classified as high-risk. They followed the BCH-HR-NB-2007 protocol, an intensive 18-month multi-modal regimen including:
- Induction: Multi-agent chemotherapy.
- Local Control: Surgical resection and external beam radiation.
- Consolidation: Myeloablative chemotherapy followed by autologous stem cell rescue.
- Maintenance: Isotretinoin therapy.
Data Analysis
Researchers utilized Kaplan-Meier survival curves and log-rank tests to evaluate Event-Free Survival (EFS) and Overall Survival (OS). Genetic testing for MYCN amplification and chromosomal G-banding was performed for risk stratification.
Clinical Presentation and the "Ophthalmology Trap"
A significant finding of this study is the diagnostic delay caused by the localized nature of initial symptoms. Approximately 65% of the children were first seen in ophthalmology clinics for periorbital masses or bruising. In one documented case, a child received topical eye drops for two weeks before a CT scan identified the metastatic mass.
As shown in Table 1, periorbital mass and bruising were the dominant symptoms (92.5%). The primary tumor was most frequently located in the retroperitoneum or adrenal area (92.5%). Critically, periorbital metastasis was never an isolated finding; 100% of patients had concurrent bone and bone marrow metastasis at the time of diagnosis.
Biological Markers and Survival Outcomes
The biological profile of these tumors further underscores their aggression. The rate of MYCN amplification was 44.7%, nearly double the rate typically seen in the general neuroblastoma population. Elevated levels of lactate dehydrogenase (LDH) and neuron-specific enolase (NSE) were also prevalent.
Despite intensive therapy, the prognosis remains poor. The 5-year Event-Free Survival (EFS) was 6%, and the 5-year Overall Survival (OS) was 16%. As detailed in Table 3, high levels of LDH (>1500 U/L) and NSE (>370 ng/ml) were common, and 82.5% of patients experienced tumor progression or recurrence, with a median time to progression of only 9 months.
Discussion and Conclusion
Periorbital metastasis in neuroblastoma is a clinical "red flag" for systemic, high-risk disease. The high frequency of multi-organ involvement—including the lymph nodes (32.5%), dura mater (27.5%), and brain parenchyma (7.5%)—indicates that these patients require aggressive, systemic intervention from the outset.
Improving outcomes will require:
- Increased Awareness: Educating primary care providers and ophthalmologists to recognize "raccoon eyes" as a potential oncological emergency.
- Targeted Research: Investigating the biological drivers that cause certain neuroblastomas to migrate to periorbital tissues.
- Novel Therapies: Integrating immunotherapy and targeted agents into existing protocols to combat the high rates of recurrence and progression seen in this cohort.
Summary updated